Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2020 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Māori with asthma.
Pilcher J, Patel M, Smith A, Davies C, Pritchard A, Travers J, Black P, Weatherall M, Beasley R, Harwood M; SMART Study Group. Pilcher J, et al. Respirology. 2014 Aug;19(6):842-51. doi: 10.1111/resp.12319. Epub 2014 Jun 2. Respirology. 2014. PMID: 24889937 Clinical Trial.
This study investigates outcomes for Maori in a randomized controlled trial (RCT) of combination budesonide/formoterol inhaler therapy in asthma. METHODS: This 24-week multicentre RCT recruited 303 adult asthma patients, 44 …
This study investigates outcomes for Maori in a randomized controlled trial (RCT) of combination budesonide/formoter
Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma.
Hardy J, Tewhaiti-Smith J, Baggott C, Fingleton J, Semprini A, Holliday M, Hancox RJ, Weatherall M, Harwood M. Hardy J, et al. N Z Med J. 2020 Aug 21;133(1520):61-72. N Z Med J. 2020. PMID: 32994594 Clinical Trial.
AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with maintenance budesonide plus as-needed terbutaline. ...CONCLUSION: The reduction in severe exacerbation risk with budesonide-fo
AIM: In the PRACTICAL study, as-needed budesonide/formoterol reduced the rate of severe exacerbations compared with mainten
Predictors of severe exacerbations, poor asthma control, and β-agonist overuse for patients with asthma.
Patel M, Pilcher J, Reddel HK, Qi V, Mackey B, Tranquilino T, Shaw D, Black P, Weatherall M, Beasley R; SMART Study Group. Patel M, et al. J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):751-8. doi: 10.1016/j.jaip.2014.06.001. Epub 2014 Jul 25. J Allergy Clin Immunol Pract. 2014. PMID: 25439367 Clinical Trial.
OBJECTIVE: To investigate characteristics that predict subsequent adverse outcomes in asthma. METHODS: An independent 24-week, randomized controlled trial of 303 adult patients with asthma who are at risk, which compared the efficacy of SMART (single budesonide
OBJECTIVE: To investigate characteristics that predict subsequent adverse outcomes in asthma. METHODS: An independent 24-week, random …